Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.

摘要: Abstract CKD-501 (i.e., lobeglitazone), a potent agonist for both PPARα/γ, is new drug that has potential clinical applications in the management of type-2 diabetes. The objective this study was to develop rapid and sensitive method determination rat plasma assess applicability assay pharmacokinetic studies. Rat samples were processed using fast flow protein precipitation (FF-PPT) then introduced onto an LC–MS/MS system quantification. analyte rosiglitazone, internal standard, analyzed by multiple reactions monitoring (MRM) at m / z transitions 482.0 → 258.0 358.0 → 135.0 standard. lower limit quantification (LLOQ) determined 50 ng/mL, with acceptable linearity range from 50 10,000 ng/mL ( R  > 0.999). Validation parameters such as accuracy, precision, dilution, recovery, matrix effect stability found be within acceptance criteria validation guidelines, indicating applicable estimating concentration studied. readily quantifiable up 24 h post-dose rats had received oral dose 1 mg/kg. These observations suggest, therefore, validated can used studies small animals rat.